PriceTargets.com logo

Athira Pharma - ATHA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $13.83
  • Forecasted Upside: 2,256.62%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.59 As of 12/17/2024 01:00 AM ET
▲ +0.01 (1.73%)

This chart shows the closing price for ATHA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Athira Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ATHA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ATHA

Analyst Price Target is $13.83
▲ +2,256.62% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Athira Pharma in the last 3 months. The average price target is $13.83, with a high forecast of $22.00 and a low forecast of $0.50. The average price target represents a 2,256.62% upside from the last price of $0.59.

This chart shows the closing price for ATHA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Athira Pharma. This rating has held steady since August 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/19/2024MizuhoDowngradeOutperform ➝ Neutral$5.00 ➝ $0.50
9/4/2024Rodman & RenshawDowngradeBuy ➝ Neutral
9/4/2024BTIG ResearchDowngradeBuy ➝ Neutral
9/4/2024JMP SecuritiesDowngradeOutperform ➝ Market Perform
8/19/2024Rodman & RenshawInitiated CoverageBuy$22.00
6/20/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$19.00 ➝ $19.00
5/16/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$19.00
8/11/2023JMP SecuritiesLower TargetOutperform ➝ Outperform$20.00 ➝ $19.00
5/15/2023MizuhoLower Target$6.00 ➝ $5.00
3/30/2023BTIG ResearchLower TargetBuy$33.00 ➝ $10.00
10/17/2022JMP SecuritiesUpgradeMarket Perform ➝ Outperform$20.00
7/6/2022MizuhoInitiated CoverageBuy$6.00
6/23/2022Stifel NicolausDowngradeBuy ➝ Hold$36.00 ➝ $5.00
6/23/2022JMP SecuritiesDowngradeOutperform ➝ Market Perform
6/22/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
5/10/2022BTIG ResearchInitiated CoverageBuy$33.00
4/21/2022Berenberg BankInitiated CoverageBuy$33.00
3/25/2022JMP SecuritiesReiterated RatingBuy$51.00
12/15/2021The Goldman Sachs GroupInitiated CoverageNeutral$16.00
8/30/2021JMP SecuritiesReiterated RatingBuy$51.00
10/13/2020Jefferies Financial GroupInitiated CoverageBuy$30.00
10/13/2020JMP SecuritiesInitiated CoverageOutperform$51.00
10/13/2020Stifel NicolausInitiated CoverageBuy$36.00
10/13/2020The Goldman Sachs GroupInitiated CoverageBuy$53.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.75 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 5 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 11 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
Mentions as of
9/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Athira Pharma logo
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Read More

Today's Range

Now: $0.59
Low: $0.56
High: $0.59

50 Day Range

MA: $0.58
Low: $0.42
High: $0.80

52 Week Range

Now: $0.59
Low: $0.41
High: $4.30

Volume

289,408 shs

Average Volume

1,573,466 shs

Market Capitalization

$22.70 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.99

Frequently Asked Questions

What sell-side analysts currently cover shares of Athira Pharma?

The following Wall Street research analysts have issued stock ratings on Athira Pharma in the last twelve months: BTIG Research, JMP Securities, Mizuho, and Rodman & Renshaw.
View the latest analyst ratings for ATHA.

What is the current price target for Athira Pharma?

0 Wall Street analysts have set twelve-month price targets for Athira Pharma in the last year. Their average twelve-month price target is $13.83, suggesting a possible upside of 2,256.6%. Rodman & Renshaw has the highest price target set, predicting ATHA will reach $22.00 in the next twelve months. Mizuho has the lowest price target set, forecasting a price of $0.50 for Athira Pharma in the next year.
View the latest price targets for ATHA.

What is the current consensus analyst rating for Athira Pharma?

Athira Pharma currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ATHA, but not buy more shares or sell existing shares.
View the latest ratings for ATHA.

What other companies compete with Athira Pharma?

Other companies that are similar to Athira Pharma include PowerUp Acquisition, 23andMe, CytomX Therapeutics, Adlai Nortye and Karyopharm Therapeutics. Learn More about companies similar to Athira Pharma.

How do I contact Athira Pharma's investor relations team?

The company's listed phone number is 425-620-8501 and its investor relations email address is [email protected]. The official website for Athira Pharma is athira.com. Learn More about contacing Athira Pharma investor relations.